Mesut AkarsuSoner OnemIlker TuranGupse AdaliMeral AkdoganMurat AkyildizMurat AladagYasemin BalabanNilay DanisMurat DayangacGenco GencdalHale GokcanElif SertesenMerve GurakarMurat HarputluogluGokhan KabacamSedat KarademirMurat KiyiciRamazan IdilmanZeki Karasu2022-12-192022-12-192021https://hdl.handle.net/20.500.12899/1203The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t) ide analogs after liver transplantation.eninfo:eu-repo/semantics/openAccessHepatitis Bliver transplantationrecurrenceArticle10.5152/tjg.2021.21608329712719346092992-s2.0-85117952374WOS:000703346600001Q4